The introduction of nicotinamide for a nicotine replacement in e-cigarette and smokeless items represents a big regulatory problem for the FDA. Nicotinamide does not have nicotinic receptor agonist activity and is known to work as a sedative at superior dosages6. The claims created by Nicotine River